Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His consulting work encompasses clinical and behavioural studies of tobacco and nicotine products for regulatory submissions in the US and Europe, and he has a wealth of experience of both consumer goods and medicinal licensing submissions. His 17 years working in the Tobacco Harm Reduction arena has included roles as Senior Director of Clinical and Regulatory Affairs EMEA with JUUL Labs, Director of Tobacco Research with Celerion, and Principal Scientist and Head of Clinical Research at British American Tobacco. As well as his consulting, Ian is a Scientific Advisory Board Member with Qnovia, a medtech startup seeking authorisation for a novel NRT in the UK and the US, and is also an Independent Non-Exec Director with Advanced Inhalation Rituals (AIR), a global shisha manufacturer.

Christopher Russell, Ph.D. is a behavioural scientist and Director of Russell Burnett Research and Consultancy Ltd (RBRC), Glasgow, United Kingdom. Dr Russell leads the design, conduct, and reporting of perception and behavioural research studies of reduced risk tobacco and nicotine products, including electronic nicotine delivery systems (ENDS, vaping products), heated tobacco products, and nicotine pouches. Studies are designed to yield a range of cross sectional and longitudinal evidence on: (i) the likelihood that tobacco users and non users will initiate use of a new product; (ii) how adult consumers actually use a new product in everyday life; (iii) how cigarette smoking behaviour changes over time concurrent with new product use (e.g., switching, reduction); and (iv) behavioural intentions, risk perceptions, and subjective effects of a new product. These sources of evidence can inform regulatory evaluations of the potential impact of marketing a new tobacco/nicotine product on future tobacco/nicotine use behaviour and population health.

Piotr is a Senior Advisor, U.S. Regulatory Policy & Director, U.S. Post-market Regulatory Affairs at PMI. He joined PMI in 2017 as a Regional Head Regulatory & Scientific Affairs for the EU Region. Piotr is a trained pharmacist, he graduated from the Medical University of Warsaw in Poland. He joined PMI from the European Medicines Agency (EMA) where was responsible for the coordination of evaluations and supervision of medicines for human use. In his current role, he serves as a principal regulatory policymaker, facilitates coordination of regulatory work across United States, Switzerland and Sweden, and provides regulatory intelligence to drive U.S. regulatory strategies and tactics for post-market submissions and activities. Leads development and implementation of regulatory-related activities to maintain FDA authorizations to market smoke-free products. As a pharmacist, Piotr is a believer and keen advocate of tobacco harm reduction strategies and supports PMI’s ambition to deliver a smoke-free future.

Elizabeth Becker serves as Senior Director, Population Science within the Regulatory Sciences organization of Altria Client Services (ALCS) in Richmond, VA. In this role, she leads a team of scientists who develop and execute perception and behavior research and narrative strategies to support product applications and regulatory submissions. Elizabeth oversees research to understand the impact of new products, claims and marketing on tobacco user and nonuser perceptions, intentions, and behaviors. Since 2005, Elizabeth has held a variety of positions across Altria. Elizabeth started her career supporting underage tobacco prevention and cessation support research and has since held roles in Corporate Communications and Innovation. Prior to joining Regulatory Sciences in 2018, Elizabeth led Altria’s Corporate Responsibility efforts. Master Business Administration, University of Massachusetts Amherst, Amherst, 2010 B.S. Psychology, Virginia Commonwealth University, 2004

Autumn is a toxicologist who has been conducting health research of reduced risk nicotine delivery products for over a decade. She has over 20 years of experience in the field of toxicology, which includes a diverse background working with consumer product manufacturers, pharmaceutical research and development teams, and various large and small clients to address complex toxicology issues during product development and in preparation of regulatory dossiers around the globe. She has developed PMTA strategies and numerous submissions for device, liquid, and pouch manufacturers. She has also developed risk assessment strategies to assess the potential health effects of ENDS products and to facilitate product design and development. Her experience has led to effective communications with governmental regulators in scientific advisory meetings.